Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURNING trial: carboplatin + nab-paclitaxel + tremelimumab + durvalumab for TTF-1-negative advanced non-squamous NSCLC
jRCTs051240242Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel, tremelimumab and durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: 12-month progression-free survival rate. Started Mar 2025; status: recruiting.
02
Drugs
carboplatinpaclitaxeltremelimumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051240242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240242.